How to Cite
Abstract
The article presents the world experience of cytoreductive surgery for ovarian cancer (OC) according to literature data and also estimates the thirteen-year experience of the Oncogynecology Department of the N.N. Petrov National Medical Research Center of Oncology in the treatment of OC patients. Materials and methods: In order to analyze the results of treatment for thirteen years it is proposed a comparative evaluation of results of primary and interval cytoreductive operations in 213 patients with OC. For this purpose all patients depending on the start of treatment were divided into two groups: a group of patients with an advanced OC where treatment started with neoadjuvant chemotherapy and a group of patients with an advanced OC where primary cytoreductive surgery was performed at the start of treatment. In these groups the long-term results of treatment were studied: platinum-free interval and life expectancy.
Results: When studying the effect of a number of neoadjuvant chemotherapy courses on long-term results of treatment it was established that the best results for platinum-free interval were obtained in a 3-course group of neoadjuvant chemotherapy - platinum-free interval was 9.6 months compared to 6.9 and 4.7 months in groups of 4 and> 5 courses although the differences in the groups did not reach statistically significant rates (p = 0.337). The increase in a number of postoperative chemotherapy courses in our study also statistically was unreliable and had a negative effect on survival: patients from the neoadjuvant chemotherapy group with> 3 courses of postoperative chemotherapy had 9.6 months versus 11.7 months in patients with 3 courses p = 0.787); life expectancy was 35.6 months compared to 30.9 months respectively (p = 0.968). The same tendency was also observed in patients from the primary cytoreduction group: in the group of patients with> 3 courses of postoperative chemotherapy platinum-free interval was 10.2 months compared to 16.3 months in patients with 3 courses (p = 0.312); life expectancy was 54.4 months compared with 48.7 months respectively (p = 0.435). The Kaplan-Meier survival estimation revealed a statistically significant improvement in life expectancy index for patients from the primary cytore-duction group (median survival time 53.7 months, 95 % CI 41.9-73.6 months) compared to patients in the neoadjuvant chemotherapy group (median life expectancy 33.0 months, 95 % CI 20.6-42.0 months, p <0.000001).
References
Meigs J.V. Tumors of the Female Pelvic Organs. -New York: Macmillan, 1934.
Griffths C.T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma//Natl. Cancer Inst. Monogr. -1975. -Vol. 42. -P 101-104.
Hoskins W.J., Bundy B.N., Thigpen J.T. et al. The infuence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage iii epithelial ovarian cancer: a Gynecologic Oncology Group Study//Gynecol. Oncol. -1992. -Vol. 47. -P 159-166.
Hoskins W.J., McGuire W.P, Brady M.F. et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma//Am. J. Obstet. Gynecol. -1994. -Vol. 170. -P 974-979.
Polterauer S., Vergote I., Concin N. et al. Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer//Int. J. Gynecol. Cancer. -2012. -Vol. 22. -P 380-385.
Bookman M.A., Brady M.F., McGuire W.P. et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup//J. Clin. Oncol. -2009. -Vol. 27(9). -P. 1419-1425.
Sehouli J., Senyuva F., Fotopoulou C. et al. Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data//J. Surg. Oncol. -2009. -Vol. 99. -P 424-427.
Ataseven B., Grimm C., Harter P et al. Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV//Gynecol. Oncol. -2016. -Vol. 140. -P. 215-220.
Fotopoulou C., Richter R., Braicu E.I. et al. Can complete tumor resection be predicted in advanced primary epithelial ovarian cancer? A systematic evaluation of 360 consecutive patients//Eur. J. Surg. Oncol. -2010. -Vol. 36. -P. 1202-1210.
Ovarian cancer. NCCN Clinical Practice Guidelines in Oncology, 2010://www.nccn.org
European Society for Medical Oncology (ESMO) Committees Annals of Oncology, October 2010://www.esmo.org.
du Bois A., Reuss A., Pujade-Lauraine E. et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian Cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO)//Cancer. -2009. -Vol. 115(6). -P. 1234-1244.
du Bois A., Kristensen G., Ray-Coquard I. et al. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial//Lancet Oncol. -2016. -Vol. 17(1). -P 78-89.
Bristow R.E., Tomacruz R.S., Armstrong D.K. et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis//J. Clin. Oncol. -2002. -Vol. 20(5). -P 12481259.
Vergote I., DeWever I., Tjalma W. et al. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients//Gynecol. Oncol. -1998. -Vol. 71. -P. 431-436.
Hunter R.W., Alexander N.D., Soutter W.P. Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery and independent determinant of prognosis?//Am. J. Obstet. Gynecol. -1992. -Vol. 166. -P. 504-511.
Bristow R.E., Tomacruz R.S., Armstrong D.K. et al. survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis//J. Clin. Oncol. -2002. -Vol. 20. -P 12481259.
Aletti G.D., Gostout B.S., Podratz K.C., Cliby W.A. Ovarian cancer surgical respectability: relative impact of disease, patient status, and surgeon//Gynecol. Oncol. -2006. -Vol. 100. -P. 33-37.
Huober J., Meyer A., Wagner U., Wallwiener D. The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer//J. Cancer Res. Clin. Oncol. -2002. -Vol. 128. -P. 153-160.
Salani R., Axtell A., Gerard M. et al. Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer//Gynecol. Oncol. -2008. -Vol. 108. -P. 271-275.
Suidan R.S., Ramirez P.T., Sarasohn D.M. et al. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer//Gynecol. Oncol. -2014. -Vol. 134(3). -P. 455-461.
Karlsen M.A., Fagö-Olsen C., Hogdall E. et al. A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC-IV ovarian cancer-a part of the Danish prospective pelvic mass study//Tumour. Biol. -2016. -Vol. 37(9). -P. 12619-12626.
Salani R., Axtell A., Gerardi M. et al. Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer//Gynecol. Oncol. -2008. -Vol. 108(2). -P. 271-275.
Portilla A.G., Shigeki K., Dario B. et al. The intraoperative staging systems in the management of peritoneal surface malignancy//J. surg. Oncol. -2008. -Vol. 98. -P. 228-231.
Sugarbaker P.H. A perspective on clinical research strategies in carcinoma of the large bowel//World J. surg. -1991. -Vol. 15. -P. 609-616.
Sugarbaker P.H. Pseudomyxoma peritonei. A cancer whose biology is characterized by a redistribution phenomenon//Ann. surg. -1994. -Vol. 219. -P. 109
Sugarbaker P.H., Jablonski K.A. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy//Ann. surg. -1995. -Vol. 221. -P 124-132.
Rosendahl M., Harter P., Bjorn S.F., Hogdall C. specific Regions, Rather than the Entire Peritoneal Carcinosis Index, are Predictive of Complete Resection and survival in Advanced Epithelial Ovarian Cancer//Int. J. Gynecol. Cancer. -2018. -P. 256-260.
Vergote I., Tropé C.G., Amant F. et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer//N. Engl. J. Med. -2010. -Vol. 363. -P. 943-953.
Vergote I., Trope C., Amant F. et al. EORTC-GCG/NCIC-CTG randomised trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIC-IV ovarian, fallopian tube and peritoneal cancer (OVCA). Presented at the 12th Biennial Meeting of the Interna tional Gynecologic Cancer society, 2008. -Bangkok. Abstr 1767.
Kehoe s., Hook J., Nankivell M. et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUs): an open-label, randomised, controlled, non-inferiority trial//Lancet. -2015. -Vol. 386. -P. 249-257.
Kehoe s., Hook J., Nankivell M. et al. Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: results from the MRC CHORUs trial//J. Clin. Oncol. -2013. -Vol. 31(suppl). -abstr 5500.
Recurrent Ovarian Cancer Ovarian Cancer National Alliance Conference sarah Adams, MD July 25, 2015.
Friedlander M., Trimble E., Tinker A. et al. Gynecologic Cancer Inter Group. Clinical trials in recurrent ovarian cancer//Int. J. Gynecol. Cancer. -2011. -Vol. 21. -р 771-775.
Кормош Н.Г. Геометрия остаточной опухоли у диссеминированных больных раком яичников/VI съезд онкологов и радиологов стран СНГ. Материалы съезда. -M., 2010.
Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome.sugarbaker PH//Eur. J. surg. Oncol. -2001. -Vol. 27(3). -P. 239-243.
Bristow R.E., Chi D.S. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis//Gynecol. Oncol. -2006. -Vol. 103(3). -P 1070-1076.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2018